Apellis Pharmaceuticals, Inc. (APLS)

Cómo genera ingresos

Money comes in three ways. First and foremost, U.S. product sales: Apellis sells SYFOVRE and EMPAVELI to a small set of specialty pharmacies and specialty distributors, which in turn supply retina practices and treatment centres; revenue is booked net of rebates, discounts and chargebacks, and payment terms run 30–65 days for EMPAVELI and 60–150 days for SYFOVRE. In 2025 net product revenue was $689.4 million, slightly below the $710.0 million of 2024, because higher rebates more than offset higher volume. Second, the Sobi collaboration: Apellis manufactures and supplies pegcetacoplan to Sobi ($26.2 million in 2025) and earns royalties on Sobi's ex-U.S. sales ($13.2 million in 2025). Third, one-off payments from that same partnership: in July 2025 Apellis sold Sobi a 90% reduction of its future royalty obligations for $275.0 million up front, recognised in 2025 revenue, plus a $25.0 million milestone paid in February 2026 after EMA approval of Aspaveli. That $275.0 million is the reason total revenue jumped to $1,003.8 million in 2025 from $781.4 million in 2024 even though product sales fell.

Ingresos por segmento

What protects Apellis is regulatory and legal, not commercial: FDA approvals for two products, patents on pegcetacoplan licensed in part from the University of Pennsylvania, orphan designations, and the sheer cost and time it takes anyone else to run the trials needed to treat these diseases. That is a real barrier, but a narrow one. The company's own risk factors state that it faces substantial competition and that others may develop or commercialise products before it does — in geographic atrophy a rival complement inhibitor is already approved and selling. SYFOVRE revenue fell in 2025, which is what an eroding position looks like in the numbers. The 10-K also warns that patents may expire before or shortly after a candidate reaches the market, and that the company may lose licensed rights if it fails to meet its obligations to its licensors.

Demand does not follow the economic cycle. Geographic atrophy, PNH and C3 glomerulopathy are progressive diseases: a patient who needs an injection needs it in a recession too, and the bill is paid by insurers and Medicare rather than out of household budgets. What actually moves Apellis's volumes is clinical and administrative, not macroeconomic — how many retina specialists decide the benefit is worth a repeated eye injection, how many patients stay on treatment rather than dropping out, whether payors keep covering the drug and at what net price, and how many treatment centres adopt EMPAVELI for the kidney indications approved in July 2025. That is visible in 2025: volumes grew but net revenue for SYFOVRE fell, because rebates absorbed more than the extra units brought in. Competitive share loss, not the economy, is the swing factor.

Riesgos clave

• The whole business rests on two drugs being accepted — The company warns it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community that EMPAVELI and SYFOVRE need to be commercially successful, in which case it may not generate significant revenues or remain profitable, and the market opportunity may prove smaller than it estimates.
• Safety or efficacy could look worse later than it did in the trials — Apellis discloses that it or others may later discover that EMPAVELI or SYFOVRE is less effective than previously believed, or causes safety issues that were not identified in clinical trials, which could compromise its ability, or that of its collaborators, to market the product. It separately notes that questions about SYFOVRE's benefit/risk profile may reduce market acceptance and hurt product revenues.
• Substantial competition — The filing states that the company faces substantial competition, which may result in others discovering, developing or commercialising products before or more successfully than Apellis does.
• Few customers, and a lot of money tied up in receivables — Apellis flags that it carries substantial accounts receivable and that delays in collecting them, or a failure to collect them, could have a material adverse effect on its cash flows and results of operations. In practice it sells to a handful of specialty pharmacies and distributors on payment terms that stretch to 150 days for SYFOVRE, and it sold $199.4 million of receivables to a financial institution in 2025 under a factoring agreement.
• Debt covenants and repayment — The 10-K warns that the terms of its indebtedness could adversely affect operations and limit its ability to plan for or respond to changes in the business, and that if it cannot comply with the restrictions in its debt financing agreements, repayment of existing indebtedness could be accelerated. Its $425.4 million of convertible notes mature on 15 September 2026 and were reclassified as current liabilities at year-end 2025.
• Pricing, reimbursement and healthcare legislation — The company discloses that EMPAVELI, SYFOVRE or any future product may become subject to unfavourable pricing regulations, third-party payor reimbursement practices or healthcare reform initiatives, and that current and future legislation may increase the difficulty and cost of obtaining reimbursement and affect the prices it can obtain. It must also make its case for coverage to each payor separately, with no assurance that adequate reimbursement will be obtained or applied consistently.
• Dependence on the Sobi collaboration and on third parties — The filing states that prospects for developing and commercialising its product candidates depend in part on the success of current and future collaborations, and that outside the United States revenues may be lower than if Apellis marketed and sold products directly. It also relies on third parties to run its clinical trials and warns that its business could be harmed if they do not perform satisfactorily.
• History of losses and no guarantee that profitability lasts — Apellis states that it has incurred significant losses since inception, expects to incur significant expenses, and may never achieve or maintain profitability. It adds that raising additional capital may dilute stockholders, restrict operations or force it to relinquish rights to its technologies or product candidates.
• Litigation naming the company and its CEO — The company discloses that it and its chief executive officer have been named as defendants in lawsuits that could result in substantial costs and divert management's attention.

Los principales clientes representan el 90% de los ingresos

Extremely concentrated, in the way typical of specialty pharma. Apellis does not sell to patients or to hospitals directly; it sells to a handful of specialty pharmacies and specialty distributors that then serve the clinics. In 2025 three customers each accounted for 10% or more of gross product revenues: Customer D 58%, Customer C 19% and Customer A 13% — about 90% between them, on a similar footing to 2024. On the balance sheet the picture is the same: Customer D was 66% and Customer C 22% of product sales receivable at 31 December 2025. Losing or renegotiating with one of these intermediaries would touch a very large share of the top line at once. The end-users, however, are thousands of retina practices and treatment centres, so the concentration is in the distribution channel rather than in actual demand.